Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations

(2020) Zsofia Sztupinszki et al.   CLINICAL CANCER RESEARCH

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

(2020) Johann S. De Bono et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic targeting of the DNA damage response in prostate cancer

(2020) Catherine H. Marshall et al.   CURRENT OPINION IN ONCOLOGY

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer

(2020) Harsimar Kaur et al.   CLINICAL CANCER RESEARCH

PARP inhibitors in prostate cancer: time to narrow patient selection?

(2020) Mark C. Markowski et al.   Expert Review of Anticancer Therapy

Etiologic Index — A Case-Only Measure of BRCA1/2–Associated Cancer Risk

(2020) Raymond Hughley et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

(2020) Mark C. Markowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

(2020) Wassim Abida et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

(2019) Piper Nicolosi et al.   JAMA Oncology

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

(2019) Catherine H. Marshall et al.   EUROPEAN UROLOGY

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

(2019) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour lineage shapes BRCA-mediated phenotypes

(2019) Philip Jonsson et al.   NATURE

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

(2019) Daniel E. Spratt et al.   CLINICAL CANCER RESEARCH

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

(2018) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers

(2018) Britta Weigelt et al.   JNCI-Journal of the National Cancer Institute

Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

(2018) Euan A. Stronach et al.   MOLECULAR CANCER RESEARCH

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy

(2018) Priscilla Léon et al.   WORLD JOURNAL OF UROLOGY

The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers

(2018) Britta Weigelt et al.   JNCI-Journal of the National Cancer Institute

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

(2018) Jai N. Patel et al.   BRITISH JOURNAL OF CANCER

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

(2017) Rong Na et al.   EUROPEAN UROLOGY

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

(2017) Paz Polak et al.   NATURE GENETICS

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

(2016) M. L. Telli et al.   CLINICAL CANCER RESEARCH

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas

(2015) Carlos L. Morais et al.   PROSTATE

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

(2014) Emilie Lalonde et al.   LANCET ONCOLOGY

Integrated analysis of germline and somatic variants in ovarian cancer

(2014) Krishna L. Kanchi et al.   Nature Communications

Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2

(2013) Lucia Guidugli et al.   HUMAN MUTATION

Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas

(2011) Alcides Chaux et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

Genomic instability — an evolving hallmark of cancer

(2010) Simona Negrini et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY